BR112022015011A2 - Método para tratar um sujeito que sofre de tumor de carcinoma adrenocortical e tendo excesso de cortisol, e, composição farmacêutica para tratar carcinoma adrenocortical - Google Patents

Método para tratar um sujeito que sofre de tumor de carcinoma adrenocortical e tendo excesso de cortisol, e, composição farmacêutica para tratar carcinoma adrenocortical

Info

Publication number
BR112022015011A2
BR112022015011A2 BR112022015011A BR112022015011A BR112022015011A2 BR 112022015011 A2 BR112022015011 A2 BR 112022015011A2 BR 112022015011 A BR112022015011 A BR 112022015011A BR 112022015011 A BR112022015011 A BR 112022015011A BR 112022015011 A2 BR112022015011 A2 BR 112022015011A2
Authority
BR
Brazil
Prior art keywords
adrenocortical carcinoma
treat
cell
sgrm
grm
Prior art date
Application number
BR112022015011A
Other languages
English (en)
Inventor
Greenstein Andrew
Grauer Andreas
Shepherd Stacie
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of BR112022015011A2 publication Critical patent/BR112022015011A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

USO DE UMA COMBINAÇÃO DE UM MODULADOR DO RECEPTOR DE GLICOCORTICOIDE SELETIVO (SGRM) E UM INIBIDOR DO PONTO DE CHECAGEM DE ANTICORPO, E, COMPOSIÇÃO FARMACÊUTICA PARA TRATAR CARCINOMA ADRENOCORTICAL. Métodos e composições para tratar um sujeito que sofre de carcinoma adrenocortical e tendo excesso de cortisol são descritos. Os métodos proveem benefícios terapêuticos incluindo a redução de carga tumoral ACC, restauração de caminhos sinalizadores de célula T e célula matadora natural (NK), aumento na infiltração de célula T e célula NK no tumor ACC, redução de infiltração de neutrófilo no tumor ACC no paciente e outros benefícios terapêuticos. Os métodos incluem administração de um modulador de receptor de glicocorticoide (GRM) (que pode ser um modulador do receptor de glicocorticoide seletivo (SGRM)) e um inibidor do ponto de checagem de anticorpo. Nas modalidades, o GRM (por exemplo, um SGRM) é oralmente administrado. O GRM pode ser um composto não esteroidal compreendendo: uma estrutura de azadecalina fundida; uma estrutura de azadecalina fundida à heteroaril cetona ou uma estrutura de azadecalina octa-hidro fundida.
BR112022015011A 2020-01-29 2021-01-26 Método para tratar um sujeito que sofre de tumor de carcinoma adrenocortical e tendo excesso de cortisol, e, composição farmacêutica para tratar carcinoma adrenocortical BR112022015011A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062967517P 2020-01-29 2020-01-29
US202063040941P 2020-06-18 2020-06-18
US202063125630P 2020-12-15 2020-12-15
PCT/US2021/015124 WO2021154750A1 (en) 2020-01-29 2021-01-26 TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS

Publications (1)

Publication Number Publication Date
BR112022015011A2 true BR112022015011A2 (pt) 2022-09-20

Family

ID=77079925

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015011A BR112022015011A2 (pt) 2020-01-29 2021-01-26 Método para tratar um sujeito que sofre de tumor de carcinoma adrenocortical e tendo excesso de cortisol, e, composição farmacêutica para tratar carcinoma adrenocortical

Country Status (13)

Country Link
US (1) US20230053364A1 (pt)
EP (1) EP4096663A4 (pt)
JP (1) JP2023516885A (pt)
KR (1) KR20220133275A (pt)
CN (1) CN115361952A (pt)
AU (1) AU2021214938B2 (pt)
BR (1) BR112022015011A2 (pt)
CA (1) CA3165708A1 (pt)
CL (1) CL2022002015A1 (pt)
IL (1) IL294862A (pt)
MX (1) MX2022009315A (pt)
WO (1) WO2021154750A1 (pt)
ZA (1) ZA202207893B (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2313296T3 (es) * 2004-01-09 2009-03-01 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoides de azadecalina.
IL297201A (en) * 2016-03-01 2022-12-01 Corcept Therapeutics Inc Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors

Also Published As

Publication number Publication date
EP4096663A4 (en) 2023-10-25
US20230053364A1 (en) 2023-02-23
MX2022009315A (es) 2022-08-22
CA3165708A1 (en) 2021-08-05
CL2022002015A1 (es) 2023-01-20
ZA202207893B (en) 2023-12-20
JP2023516885A (ja) 2023-04-21
AU2021214938A1 (en) 2022-09-08
KR20220133275A (ko) 2022-10-04
CN115361952A (zh) 2022-11-18
AU2021214938B2 (en) 2024-02-08
IL294862A (en) 2022-09-01
WO2021154750A1 (en) 2021-08-05
EP4096663A1 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
Ganguly et al. Melatonin promotes angiogenesis during protection and healing of indomethacin‐induced gastric ulcer: role of matrix metaloproteinase‐2
Liang et al. Lymphatic endothelial cells efferent to inflamed joints produce iNOS and inhibit lymphatic vessel contraction and drainage in TNF-induced arthritis in mice
Brzozowski et al. Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor
Cuellar et al. Ghrelin-induced activation of cAMP signal transduction and its negative regulation by endocannabinoids in the hippocampus
Wu et al. Protective role of β-patchoulene from Pogostemon cablin against indomethacin-induced gastric ulcer in rats: Involvement of anti-inflammation and angiogenesis
Huang et al. Capsaicin protects cortical neurons against ischemia/reperfusion injury via down-regulating NMDA receptors
Buttar et al. The “aspirin” of the new millennium: cyclooxygenase-2 inhibitors
Yu et al. Bradykinin enhances cell migration in human prostate cancer cells through B2 receptor/PKCδ/c‐Src dependent signaling pathway
BRPI0317463B8 (pt) composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
Priyanka et al. Bacopa monnieri and l-deprenyl differentially enhance the activities of antioxidant enzymes and the expression of tyrosine hydroxylase and nerve growth factor via ERK 1/2 and NF-κB pathways in the spleen of female Wistar rats
Schwieger‐Briel et al. Mechanism of Oleogel‐S10: A triterpene preparation for the treatment of epidermolysis bullosa
El-Shiekh et al. Russelioside B; A pregnane glycoside for treatment of gastric ulcer via modulation of heat shock protein-70 and vascular endothelial growth factor
Katsinelos et al. Aggressive treatment of acute anal fissure with 0.5% nifedipine ointment prevents its evolution to chronicity
Ko et al. Combination therapy with polydeoxyribonucleotide and proton pump inhibitor enhances therapeutic effectiveness for gastric ulcer in rats
Liu et al. Betulinic acid attenuates liver fibrosis by inducing autophagy via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway
Yue et al. Morin exerts anti‐arthritic effects by attenuating synovial angiogenesis via activation of peroxisome proliferator activated receptor‐γ
Emery Clinical implications of selective cyclooxygenase-2 inhibition
Lu et al. Glatiramer acetate inhibits degradation of collagen II by suppressing the activity of interferon regulatory factor-1
Lixing et al. Saikosaponin-d-mediated downregulation of neurogenesis results in cognitive dysfunction by inhibiting Akt/Foxg-1 pathway in mice
BR112022015011A2 (pt) Método para tratar um sujeito que sofre de tumor de carcinoma adrenocortical e tendo excesso de cortisol, e, composição farmacêutica para tratar carcinoma adrenocortical
BR0309825A (pt) Método e composição farmacêutica para reduzir a dor em um mamìfero que sofra de um neoplasma
Kim et al. Therapeutic effect of guggulsterone in primary cultured orbital fibroblasts obtained from patients with graves’ orbitopathy
Wang et al. Galangin attenuates IL-1β-induced catabolism in mouse chondrocytes and ameliorates murine osteoarthritis
Aasarød et al. Effects of the histamine 1 receptor antagonist cetirizine on the osteoporotic phenotype in H+/K+ ATPase beta subunit KO mice
Yang et al. Casticin suppresses RANKL‑induced osteoclastogenesis and prevents ovariectomy‑induced bone loss by regulating the AKT/ERK and NF‑κB signaling pathways